SQ-31765
SQ-31765 Basic information
- Product Name:
- SQ-31765
- Synonyms:
-
- 2H-1-Benzazepin-2-one, 3-(acetyloxy)-1-[2-(dimethylamino)ethyl]-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-6-(trifluoromethyl)-, (3R,4S)-
- SQ31765,SQ 31765
- 3-(Acetyloxy)-1-(2-(dimethylamino)ethyl)-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-6-(trifluromethyl)-2H-1-benzazepine-2-one
- CAS:
- 138383-07-0
- MF:
- C24H27F3N2O4
- MW:
- 464.48
- Mol File:
- 138383-07-0.mol
SQ-31765 Chemical Properties
- storage temp.
- Store at -20°C
- solubility
- Soluble in DMSO
SQ-31765 Usage And Synthesis
Uses
SQ-31765 is a benzazepine calcium channel blocker.
in vivo
SQ-31765 (SQ 31,765) can reduce the severity of ischemia in a manner which is independent of changes in myocardial blood flow or hemodynamic alterations. Anesthetized dogs are given saline (n=6), SQ-31765 (n=6; 0.2 mg/kg) or SQ 32,189 (n=6; 0.2 mg/kg) i.v. 10 min before ischemia. The effect on pacing-induced ST-segment elevation (pacing+left anterior descending coronary artery stenosis) and myocardial blood flow are determined. SQ-31765 reduces ST-elevation (P<0.05) compared to saline at 10, 40 and 70 min after infusion (5.9±1.4 and 12.0±1.4 mV, respectively, at 70 min). Left anterior descending coronary artery stenosis during atrial pacing resulted in a significant reduction in subendocardial flow in all groups before drug infusion (41±7, 44±7 and 35±9 mL/min/100 g for saline, SQ-31765 and SQ 32,189, respectively)[1].
References
[1] Grover GJ, et al. Anti-ischemic and vasorelaxant effects of the new benzazepine calcium channel blocker SQ 31,765. J Pharmacol Exp Ther. 1989 Dec;251(3):1020-5. PMID:2481028
SQ-31765Supplier
- Tel
- 15911056312
- liming@bio-fount.com
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Tel
- 13348960310
- 3003867561@qq.com
- Tel
- 010-60605840 15801484223;
- psaitong@jm-bio.com
- Tel
- 4008200310
- marketing@tsbiochem.com